Patents by Inventor Anil Karbhari Shinde

Anil Karbhari Shinde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH NMDA RECEPTOR ANTAGONIST
    Publication number: 20190175586
    Abstract: The present invention relates to pure 5-HT6 receptor antagonist or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to NMDA receptor antagonist and their use in the treatment of cognitive disorders. The invention further relates to the pharmaceutical composition containing the said combination.
    Type: Application
    Filed: August 3, 2016
    Publication date: June 13, 2019
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
  • Muscarinic M1 receptor positive allosteric modulators
    Patent number: 10308620
    Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: June 4, 2019
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
  • TRIPLE COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS, ACETYLCHOLINESTERASE INHIBITORS AND NMDA RECEPTOR ANTAGONIST
    Publication number: 20190160055
    Abstract: The present invention relates to a combination of pure 5-HT6 receptor antagonist, acetylcholinesterase inhibitor and NMDA receptor antagonist. Also, the present invention provides pure 5-HT6 receptor (5-HT6R) antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and N-Methyl-D-aspartate (NMDA) receptor antagonist and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.
    Type: Application
    Filed: August 3, 2016
    Publication date: May 30, 2019
    Applicant: Suven Life Sciences Limited
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
  • COMBINATION OF HISTAMINE-3 RECEPTOR INVERSE AGONISTS WITH ACETYLCHOLINESTERASE INHIBITORS
    Publication number: 20190160075
    Abstract: The present invention relates to the combination of histamine-3 receptor inverse agonist and acetylcholinesterase inhibitor. Also, the present invention provides histamine-3 receptor (H3R) inverse agonist, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitor and their use in the treatment of cognitive disorders. The present invention further provides the pharmaceutical composition containing the said combination.
    Type: Application
    Filed: August 14, 2017
    Publication date: May 30, 2019
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
  • Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators
    Patent number: 10294217
    Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: May 21, 2019
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Ramkumar Subramanian, Vijay Sidram Benade, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • COMBINATION OF PURE 5-HT6 RECEPTOR ANTAGONISTS WITH ACETYLCHOLINESTERASE INHIBITORS
    Publication number: 20190125743
    Abstract: The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.
    Type: Application
    Filed: August 3, 2016
    Publication date: May 2, 2019
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
  • Fluoroindole Derivatives as Muscarinic M1 Receptor Positive Allosteric Modulators
    Publication number: 20180244655
    Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
    Type: Application
    Filed: July 19, 2016
    Publication date: August 30, 2018
    Applicant: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Ramkumar Subramanian, Vijay Sidram Benade, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • Active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate and dimesylate dihydrate salt of active metabolite
    Patent number: 10010527
    Abstract: The present invention is directed to active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate of formula (I). The present invention is also directed to dimesylate dihydrate salt of formula (II). The compounds of formula (I) and formula (II) are useful in the treatment of various disorders that are related to 5-HT6 receptor antagonist.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: July 3, 2018
    Assignee: SUVEN SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Ramasastri Kambhampati, Anil Karbhari Shinde, Venkateswarlu Jasti
  • MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
    Publication number: 20180155302
    Abstract: The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of preparing such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to muscarinic M1 receptor.
    Type: Application
    Filed: June 8, 2016
    Publication date: June 7, 2018
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
  • Amide compounds as 5-HT4 receptor agonists
    Patent number: 9957257
    Abstract: The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: May 1, 2018
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Abdul Rasheed Mohammed, Sangram Keshari Saraf, Narsimha Bogaraju, Ramkumar Subramanian, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Venkateswarlu Jasti
  • Indazole compounds as 5-HTreceptor agonists
    Patent number: 9951045
    Abstract: The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: April 24, 2018
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Anil Karbhari Shinde, Shankar Reddy Gagginapally, Venkateswarlu Jasti
  • AMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20180051011
    Abstract: The present invention relates to compounds of formula (I), including their stereoisomers and pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-hydroxytryptamine 4 (5-HT4) receptor.
    Type: Application
    Filed: January 7, 2016
    Publication date: February 22, 2018
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Abdul Rasheed MOHAMMED, Sangram Keshari SARAF, Narsimha BOGARAJU, Ramkumar SUBRAMANIAN, Pradeep JAYARAJAN, Gopinadh BHYRAPUNENI, Venkateswarlu JASTI
  • Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride
    Patent number: 9802896
    Abstract: The present, invention relates to a process for large scale production of N-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride of formula (I).
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: October 31, 2017
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Ramasastri Kambhampati, Venkateswarlu Jasti
  • 5-amino-quinoline-8-carboxamide derivatives as 5-HT4 receptor agonists
    Patent number: 9790211
    Abstract: The present invention relates to novel quinoline compounds of formula (I), and their pharmaceutically acceptable salts and process for their preparation. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptor agonists.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: October 17, 2017
    Assignee: Suven Life Sciences Limited
    Inventors: Ramakrishna Nirogi, Anil Karbhari Shinde, Venkateswarlu Jasti
  • ACTIVE METABOLITE OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE AND DIMESYLATE DIHYDRATE SALT OF ACTIVE METABOLITE
    Publication number: 20170273944
    Abstract: The present invention is directed to active metabolite of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate of formula (I). The present invention is also directed to dimesylate dihydrate salt of formula (II). The compounds of formula (I) and formula (II) are useful in the treatment of various disorders that are related to 5-HT6 receptor antagonist.
    Type: Application
    Filed: October 20, 2014
    Publication date: September 28, 2017
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Ramasastri KAMBHAMPATI, Anil Karbhari SHINDE, Venkateswarlu JASTI
  • PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1-CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACETAMIDE DIHYDROCHLORIDE
    Publication number: 20170260135
    Abstract: The present, invention relates to a process for large scale production of N-[4-(1-Cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride of formula (I).
    Type: Application
    Filed: October 20, 2014
    Publication date: September 14, 2017
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Anil Karbhari SHINDE, Ramasastri KAMBHAMPATI, Venkateswarlu JASTI
  • Heteroaryl compounds as 5-HTreceptor ligands
    Patent number: 9636335
    Abstract: The present invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts and compositions containing them. The present invention also relates to a process for the preparation of above said novel compounds, and their pharmaceutically acceptable salts. The compounds of formula (I) are useful in the treatment of various disorders that are related to 5-HT4 receptors.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: May 2, 2017
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Abdul Rasheed Mohammed, Suresh Yarlagadda, Srinivasa Rao Ravella, Anil Karbhari Shinde, Ramasastri Kambhampati, Praveen Kumar Roayapalley, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Sriramachandra Murthy Patnala, Jyothsna Ravula, Venkateswarlu Jasti
  • Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate
    Patent number: 9540321
    Abstract: A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: January 10, 2017
    Assignee: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna Nirogi, Rama Sastri Kambhampati, Anil Karbhari Shinde, Venkateswarlu Jasti
  • INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
    Publication number: 20160311797
    Abstract: The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxy-tryptamine 4 (5-HT4) receptor agonists.
    Type: Application
    Filed: February 24, 2014
    Publication date: October 27, 2016
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Abdul Rasheed MOHAMMED, Anil Karbhari SHINDE, Shankar Reddy GAGGINAPALLY, Venkateswarlu JASTI
  • PROCESS FOR LARGE SCALE PRODUCTION OF 1-[(2-BROMOPHENYL)SULFONYL]-5-METHOXY-3-[(4-METHYL-1-PIPERAZINYL)METHYL]-1H-INDOLE DIMESYLATE MONOHYDRATE
    Publication number: 20160297759
    Abstract: A process suitable for adoption to large scale manufacture of 1-[(2-bromophenyl-sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate, which is a selective 5-HT6 receptor antagonist intended for the symptomatic treatment of Alzheimer's disease and other disorders of memory and cognition like Attention deficient hyperactivity, Parkinson's and Schizophrenia.
    Type: Application
    Filed: February 20, 2014
    Publication date: October 13, 2016
    Applicant: SUVEN LIFE SCIENCES LIMITED
    Inventors: Ramakrishna NIROGI, Rama Sastri KAMBHAMPATI, Anil Karbhari SHINDE, Venkateswarlu JASTI